Our latest paper with the Bardeesy lab Mass General Cancer Center out recently in Science. We describe a novel immune MOA for inhibitors of mutant IDH1 involving the upregulation of transposable elements that are sensed by the cGAS-STING pathway. science.org/doi/10.1126/sc… Explainer🧵

Really happy to share our new mini Review on One Carbon Metabolism and chromatin (fantastic job by Tiziano Bernasocchi. Out in Frontiers - Genetics frontiersin.org/journals/epige…

In a new Science Magazine study, researchers from Mass General Cancer Center and colleagues investigated a new pathway for viral mimicry underlying the anti-cancer mechanism of MIDHI. Read more: massgeneral.org/news/research-… @mjwu_tw @mangusolab

Richard I. Gregory, PhD, studies molecular mechanisms of RNA regulation in embryonic stem cells and cancer. In December, he will join UMass Chan Medical School as the next chair of the Department of Molecular, Cell & Cancer Biology: direc.to/k_TR #RNA #CancerResearch Molecular, Cell and Cancer Biology

Fantastic talk from Dr Vindhya Vijay at the prestigious #cshlcancer24 conference on a currently non-targetable subset of cholangiocarcinoma. Her work, supported by a CCF Research Fellowship, is pushing the field forward! Read her brilliant pre-print: biorxiv.org/content/10.110…

The FDA approved Servier’s IDH1 and IDH2 inhibitor vorasidenib for IDH-mutant glioma following surgery, providing the first new drug in decades for this rare cancer nature.com/articles/d4157…

Our latest paper "NaCl enhances CD8+ T cell effector functions in cancer immunotherapy" is now out Nature Immunology nature.com/articles/s4159… 🥳🎉🍾. A 🧵:

🧬🚨 Our study on novel antigens induced in glioblastoma upon treatment with epigenetic therapy is out!! This study was led by joshhjang with co-first-authors Yonghao Liang and Ju-Heon Maeng, and mentored by Ting Wang and Albert H. Kim. 5 Key Takeaways: 1/5 nature.com/articles/s4158…

In a study funded by our division, Meng-Ju Wu et al. revealed a new mechanism for viral mimicry in triggering an immune response underlying the antitumor activity of mutant isocitrate dehydrogenase 1 (IDH1) inhibitors Science Magazine science.org/doi/10.1126/sc….